HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
— Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia —
Covered in this story
Call it yourself
No calls on $HCM yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on HUTCHMED →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.